80 related articles for article (PubMed ID: 1920849)
21. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
Perreault C; Gyger M; Boileau J; Bonny Y; Cousineau S; Lacombe M; Lavallee R; Tawil E; D'Angelo G
Can Med Assoc J; 1983 Nov; 129(9):969-74. PubMed ID: 6367917
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of BMT management in children and adults.
Torlontano G; Di Girolamo G; Di Bartolomeo P; Angrilli F; Papalinetti G; Olioso P; Dragani A; Fioritoni G; Iacone A; D'Antonio D
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():59-60. PubMed ID: 2516756
[No Abstract] [Full Text] [Related]
23. Ecological investigation on intestinal bacterial flora of patients nursed in protected environmental units.
Ozawa A; Sawamura S; Nagao T; Sasaki S
Tokai J Exp Clin Med; 1980 Jan; 5(1):97-112. PubMed ID: 7385267
[TBL] [Abstract][Full Text] [Related]
24. [Autologous bone marrow transplantation].
Fujimori Y; Kakishita E
Rinsho Byori; 1995 Jul; Suppl 99():9-14. PubMed ID: 7474430
[No Abstract] [Full Text] [Related]
25. [Studies of intestinal microbial flora in the post-BMT (bone marrow transplantation) patients under a protected environment].
Yonekura S; Nagao T; Komatsuda M; Arimori S; Sawamura S; Ozawa A; Hashimoto K; Sasaki S
Kansenshogaku Zasshi; 1990 Aug; 64(8):963-6. PubMed ID: 2212765
[TBL] [Abstract][Full Text] [Related]
26. Protected environment and its utility in experimental allogeneic and xenogeneic bone marrow transplantation.
Pollard M
Tokai J Exp Clin Med; 1985 Jun; 10(2-3):175-9. PubMed ID: 2939599
[TBL] [Abstract][Full Text] [Related]
27. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
28. Reverse isolation in bone marrow transplantation: ultra-clean room compared with laminar flow technique. II. Microbiological and clinical results.
Vossen JM; van der Waay D
Rev Eur Etud Clin Biol; 1972; 17(6):564-74. PubMed ID: 4630613
[No Abstract] [Full Text] [Related]
29. Intravenous immunoglobulin: immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients.
Klaesson S; Ringdén O; Markling L; Tammik L
Transplant Proc; 1995 Dec; 27(6):3536-7. PubMed ID: 8540089
[No Abstract] [Full Text] [Related]
30. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
Liu YP; Li Z; Nador RG; Strober S
Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
[TBL] [Abstract][Full Text] [Related]
31. [Prevention and treatment of infection in patients after bone marrow transplantation].
Wiktor-Jedrzejczak W; Szczylik C
Acta Haematol Pol; 1987; 18(3-4):233-6. PubMed ID: 3132012
[No Abstract] [Full Text] [Related]
32. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
33. Early complications of bone marrow transplantation in children and adults.
Tutschka PJ
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():22-6. PubMed ID: 2516755
[No Abstract] [Full Text] [Related]
34. [Prevention of graft-vs-host disease following allogeneic bone marrow transplantation].
de Witte T; Janssen J; de Pauw B; Holdrinet R; Wessels J; Haanen C
Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1290-1. PubMed ID: 3528870
[No Abstract] [Full Text] [Related]
35. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
[No Abstract] [Full Text] [Related]
36. Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease.
Slavin S; Or R; Cividalli G; Brautbar C; Hale G; Waldmann H; Rachmilewitz E
Birth Defects Orig Artic Ser; 1988; 23(5B):313-6. PubMed ID: 3291967
[No Abstract] [Full Text] [Related]
37. [Bone marrow transplant in aplastic anemia. Current status and review of the first allogeneic transplants in Mexico].
Morales-Polanco MR; Pizzuto-Chávez J
Gac Med Mex; 1984 Feb; 120(2):49-57. PubMed ID: 6376258
[No Abstract] [Full Text] [Related]
38. Gut sterilization during bone marrow transplantation [proceedings].
Marty M; Gisselbrecht C; Gluckman E; Devergie A; Bussel A; Ducluzeau R; Perol AM
Pathol Biol (Paris); 1978 Jan; 26(1):60. PubMed ID: 358095
[No Abstract] [Full Text] [Related]
39. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
40. Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
Ghosh K; Hutchinson RM
Haematologia (Budap); 1996; 28(1):45-51. PubMed ID: 9283904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
